Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
Status:
Completed
Trial end date:
2018-10-26
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/1b, multicenter, open-label, two-part study in subjects with relapsed or
refractory MM:
- Phase 1a: single agent CWP232291. Dose-finding followed by cohort expansion at the
maximum tolerated dose (MTD) or optimal dose as determined by the Safety Review
Committee (SRC).
- Phase 1b: CWP232291 in combination with lenalidomide and dexamethasone. Dose-finding
followed by cohort expansion at the combination therapy MTD or optimal dose as
determined by the SRC.